Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Ccr5 as a potential target in cancer therapy: Inhibition or stimulation?

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Gonzalez-Martin, A.
  • Mira, E.
  • Manes, S.

publication date

  • 2012

journal

  • Anti-Cancer Agents in Medicinal Chemistry  Journal

abstract

  • Extensive evidence implicates CCR5 and its ligands in the biology of tumors, although there is considerable controversy regarding the role of this chemokine receptor in cancer progression. The discrepancies between the pro- and anti-tumor effects of CCR5 might derive from its expression by cell types with opposing functions in tumor progression and the context in which tumors originate. We propose that CCR5 is necessary for optimal activation of the adaptive immune response to tumors, and for the success of certain immunotherapeutic strategies. Since efficient activation of T cell responses has broad implications in the success of some chemoand radiotherapy protocols, activation of CCR5, rather than its inhibition, might provide new therapeutic opportunities for cancer treatment.

subject areas

  • Adaptive Immunity
  • Animals
  • Antineoplastic Agents
  • Chemokines
  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Neoplasms
  • Receptors, CCR5
scroll to property group menus

Research

keywords

  • CCR5
  • Chemokines
  • Crosspriming
  • Immune Response
  • Immunotherapy
  • Inflammation
  • Maraviroc
  • Tumor microenvironment
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1871-5206

Digital Object Identifier (DOI)

  • 10.2174/187152012803529637

PubMed ID

  • 22583417
scroll to property group menus

Additional Document Info

start page

  • 1045

end page

  • 1057

volume

  • 12

issue

  • 9

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support